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with 13,961,659KRW (1,100 KRW= 1 USD) additional cost spent compared to a patient 
in SR alone with an incremental cost-utility ratio (ICUR) of 11,638,656KRW/QALY. 
Bedaquiline plus SR had a 80% probability of being cost-effective at a willingness 
to pay threshold of 26,000,000KRW when compared with SR alone. ConClusions: 
The results of this study indicate that bedaquiline is a cost-effective option for the 
treatment of MDR (including XDR-TB patients) in the Korean settings when com-
pared to standard treatment alone.
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objeCtives: The main objetive was to evaluate the cost reduction by introduction 
of equivalent therapeutic program after the accord in the Central Pharmaceutical 
Commission in Extremadura. Methods: Retrospective observational study 
between March 2013 and March 2014. We agree that micafungin was the pref-
erential echinocandin for the same indication. Caspofungin was restricted for 
empiric treatment of fungal infection in patients with fever and neutropenia and 
Anidulafungin was used in patients with hepatic dysfunction. To quantify the 
avoided costs we extracted consumption data and costs of antifungals from the 
Pharmacy Department Multibase v.3. Program (Dominion) and compared them with 
the same period the previous year. Results: Regarding avoided costs for the period 
of the study, echinocandins costs were reduced by 353.965 euros, a 24,35 % less than 
previous year. In the first period, the echinocandin most used was caspofungin 
(51,23%) because the prescription wasn´t restricted and the physician could use 
anyone. In the second period, we observed a 31,63% increase in use in micafungin, 
the echinocandin that we evaluated the most efficient in our protocol. The use of 
caspofungin and anidulafungin decreased a 11,92% and 19,71% respectively. These 
use involved a decrease in cost too, 255.836 and 254.896 euros less about anidu-
lafungin and caspofungin use respectively. These results are consistent with the 
recommendations contained in our program (first line use of micafungin in nonim-
munosuppressed patients with candida infection). ConClusions: Our therapeutic 
program compliance was good at our hospitals, resulting in a significant decrease 
in echinocandins expenses. Maybe, the implementation of these type of programs 
in the management of high-cost drugs resulted in significant cost reductions and 
therefore in a more rational use of healthcare budgets.
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Cost ANAlysIs of resIduAl vIremIA deteCted by two reAl-tIme 
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objeCtives: The duration of current standard dual and triple therapies for HCV-G1 
is determined by assessment of early viral kinetics. We conducted a cost analysis 
to determine the main cost of treatment for a patient with HCV-G1 with dual or 
triple therapy, where the duration of the therapy (24 or 48 weeks) is guided by HCV-
RNA assay. Methods: HCV-RNA was assessed by two widely used real-time PCR-
based assays, Cobas Ampliprep/Cobas TaqMan (CAP-CTM) and Real-Time HCV (ART). 
Considering the dual therapy (PegINFα -2b and RBV) at week 12 of treatment, 16% of 
patients (27/169) were eligible to receive a shorter duration of therapy (24 weeks) 
according to CAP-CTM and 9% (16/169) to ART: 26 patients achieved SVR with CAP-
CTM and 15 with ART. Considering the triple therapy (TPV, PegINFα -2a and RBV) at 
week 12 of treatment, 60% of patients (31/52) were eligible to receive a shorter dura-
tion of therapy (24 weeks) according to CAP-CTM and 25% (13/52) to ART: 30 patients 
achieved SVR with CAP-CTM and 13 with ART. The cost analysis was conducted 
from the perspective of the Italian National Health Service (NHS). Only drugs (TPV, 
PegINFα -2b, PegINFα -2b and RBV) and tests (CAP-CTM and ART) costs were consid-
ered. Ex-factory prices (included all discounts) and National Tariffs were considered 
to appraise drug consumptions and tests, respectively. Costs were assessed in Euros 
in 2015. Results: Considering the dual therapy, the overall main treatment cost per 
patient with CAP-CTM (€ 9,743.63) was lower than with ART (€ 10,053.46). Taking into 
account the triple therapy, the overall main treatment cost per patient was lower 
with CAP-CTM (€ 31,630.69) than with ART (€ 33,463.24). ConClusions: CAP-CTM 
HCV-RNA assay was cost-saving from the Italian NHS perspective compared to ART 
HCV-RNA assay in dual (-€ 309.83 cost per patient) and triple (-€ 1,832.55 cost per 
patient) HCV therapy.
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objeCtives: Adults ≥ 65 years account for most seasonal influenza-related hospitali-
zations and deaths. A recent head-to-head RCT (FIM12, NCT01427309) demonstrated 
that a high-dose influenza vaccine (HD) was 24.2% more efficacious than a standard-
dose influenza vaccine (SD) in preventing laboratory-confirmed influenza-like illness 
among 31,989 adults ≥ 65 years. A cost-utility analysis (CUA) of HD vs. SD in FIM12 
participants was performed. Methods: Health-care resource utilization data col-
lected in the FIM12 study utilized resources (medications, non-routine medical visits, 
emergency room visits, and hospitalizations) were summarized across vaccine arms 
and unit costs were applied, using standard Canadian cost sources (in CAD), to each 
resource item (including vaccines; HD $31.82; SD $5.82) to estimate the mean total 
direct medical and societal costs associated with each vaccine. Health outcomes data 
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objeCtives: To evaluate the cost-effectiveness of an integrase inhibitor (INI), 
dolutegravir (DTG), in combination with abacavir(ABC)/lamivudine(3TC) in France, 
in treatment-naïve (TN) HIV adult patients. Methods: The ARAMIS microsimula-
tion Markov model, including HIV health states with and without opportunistic 
infection, evaluates costs and effects of first line options including INIs (raltegravir 
[RAL], elvitegravir/c), protease inhibitors (PI) (darunavir [DRV/r], atazanavir/r, lopi-
navir [LPV/r]), efavirenz (EFV) and rilpivirine at a life time horizon with a monthly 
cycle length. Efficacy and safety data were derived from phase III studies (SPRING 2, 
FLAMINGO and SINGLE including comparators RAL, DRV/r and EFV respectively) and 
network meta-analyses for other comparators. Treatment algorithms were based on 
French guidelines and experts opinion accounting for patient’s treatment history, 
including INI resistance status. Costs, from a collective perspective included rou-
tine HIV and opportunistic infection care, and death. Results: The model showed 
DTG/ABC/3TC was more effective than all other recommended regimens: patients 
stayed longer on first line, and lived longer and healthier (incremental life years 
ranged from 0.305 to 0.71 and QALYs from 0.085 to 0.28 versus RAL and LPV/r). With 
the exception of EFV, DTG was dominant compared to all strategies, with the larg-
est cost savings for INIs (incremental costs of -€ 21,556 for RAL). The cost per QALY 
gained (ICER) for DTG compared to EFV was € 6,939 (incremental QALYs and costs 
of 0.10 and +€ 692, respectively). Deterministic sensitivity analyses (DSA) showed 
that DTG was dominant compared to INIs and PIs in all DSA. Compared to EFV, the 
ICER was most sensitive to time horizon, resistance parameters, and late failure 
probability. ConClusions: DTG/ABC/3TC is cost-effective in the management of 
HIV TN patients in France. These results are mainly explained by the lower price of 
DTG/3TC/ABC compared to INIs and PIs, DTG’s superior efficacy and high barrier 
to resistance.
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objeCtives: The development of new highly effective therapies for the treatment 
of hepatitis C virus (HCV), leads to the opportunity to eradicate this infection. In a 
context characterized by a high prevalence of this pathology (i.e. Italy) the investi-
gation of the most efficient therapies to allocate resources to, is crucial. The aim of 
the study was to investigate the cost-effectiveness of Daclatasvir+Sofosbuvir+Rib
avirine therapy, compared with Sofosbuvir+Ribavirine+Peginterferone therapy for 
the treatment of HCV genotype 3 infection in cirrhotic patients within the Italian 
National Health Service. Methods: A published cohort-based Markov simulation 
model (Monarch model) was used to perform lifetime horizon analyses assuming 
the Italian National Health Service point of view. The model simulates the natural 
history of HCV infection and its complications. Patient cohorts were defined based 
on selected clinical studies and eligibility criteria defined by the Italian Medicines 
Agency. The comparator was selected considering EASL guidelines published in 
2015. The costs considered (2015) were direct medical costs, including adverse 
events costs. Utility values were influenced by health status and adverse events 
(anemia, rash, insomnia, headache, fatigue, nausea, diarrhea). Both costs and util-
ity values were discounted using a 3% rate. Results: Daclatasvir+Sofosbuvir+ 
Ribavirine for 24 weeks (100% sustained virological response – registry trial) would 
lead to a per capita increase of quality adjusted life years (QALYs) (12.46 vs. 12.10) 
and costs (56,318 € vs. 41,881 € ) compared with Sofosbuvir+Ribavirine+Peginterf- 
erone for 12 weeks (92.06% sustained virological response – PROTON, ELECTRON, 
LONESTAR studies). The incremental cost effectiveness ratio (ICER) is 39,614 € /
QALY. ConClusions: Daclatasvir+Sofosbuvir+Ribavirine therapy is likely to be 
cost effective compared with Sofosbuvir+Ribavirine+Peginterferone in genotype 3 
HCV infected cirrhotic patients, leading to an ICER below the 40,000 € /QALY thresh-
old identified by the Italian Association of Health Economics.
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objeCtives: Bedaquiline is a newly introduced agent for the treatment of mul-
tidrug-resistant tuberculosis (MDR-TB) and this study aimed to evaluate the cost 
effectiveness of adding bedaquiline to a standard regimen (SR) to treat patients with 
MDR-TB, including extensively drug resistant tuberculosis (XDR-TB) in comparison 
with standard regimen alone in South Korea. Methods: A cohort based decision 
analytic model developed in a previously published study from the UK was used 
with the following parameters: a 20 year time horizon, and a 5% discount rate for 
cost and effectiveness to evaluate incremental cost-effectiveness ratios (ICER) of 
bedaquiline plus SR and SR alone. Key parameters on clinical data were based on 
the published Phase 2trial of bedaquiline and other parameters for recurrence, 
cured, lost follow-up, surgery, death, cost and health utility were based on Korean 
data if available, otherwise the international literature data were applied. Univariate 
and probabilistic sensitivity analyses were conducted. Results: A patient on 
bedaquiline plus SR regimen had 1.20 quality adjusted life years (QALYs) longer 
